[Effects of hypolipidemic therapy on the endothelial dysfunction in patients with myocardial infarction at young age]

Area of Science:

• Cardiovascular Medicine
• Endothelial Biology
• Pharmacology

Background:

• Endothelial dysfunction is a key factor in cardiovascular disease progression.
• Myocardial infarction (MI) at a young age (<45 years) indicates significant underlying cardiovascular risk.
• Assessing endothelial function post-MI is crucial for risk stratification and management.

Purpose of the Study:

• To quantify endothelial dysfunction in young male MI survivors.
• To investigate the therapeutic effect of lipantil on endothelial function and lipid profiles.
• To evaluate the impact of hypolipidemic therapy on cardiovascular risk markers.

Main Methods:

• Vascular endothelial function assessed via brachial artery dilation during reactive hyperemia.
• Circulating desquamated endotheliocytes quantified as a marker of endothelial damage.
• Lipid metabolism parameters evaluated in 40 young male MI survivors and 40 healthy controls.
• Intervention group received 3-month lipantil therapy.

Main Results:

• Young MI survivors demonstrated significant endothelial dysfunction, including reduced brachial artery dilation and elevated endotheliocyte counts.
• Patients presented with abnormal lipid metabolism.
• Lipantil therapy led to a significant amelioration of endothelial dysfunction and improved lipid profiles.

Conclusions:

• Young patients surviving MI exhibit pronounced endothelial dysfunction.
• Hypolipidemic therapy, specifically with lipantil, can effectively reduce the severity of endothelial dysfunction and improve lipid metabolism in this population.
• These findings highlight the potential of targeted therapy to mitigate long-term cardiovascular risk in young MI survivors.